Abstract
Objective: Sublingual immunotherapy (SLIT) is currently used worldwide as an allergic rhinitis management tool. The purpose of this study was to investigate the efficacy and safety of SLIT for Asian patients with allergic rhinitis to house dust mites.
Method: Ninety-eight patients who had allergic rhinitis for dermatophagoides were included and started to receive SLIT. Symptom scores and quality of life were evaluated before and until 1 year by questionnaires. Medication score was assessed monthly by a diary medication card. Adverse effects and compliance were also investigated.
Results: All nasal and non-nasal symptoms and quality of life were significantly improved after treatment except itchy palate (P < .05). Total medication score was decreased after treatment significantly (P < .05). Some minor adverse effects was reported, however there was no systemic reaction. The drop-out rate was 19%.
Conclusion: SLIT for Korean patients with allergic rhinitis to house dust mites is an efficient and safe treatment tool.
Get full access to this article
View all access options for this article.